| 21.29 0.42 (2.01%) | 04-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 27.22 | 1-year : | 31.02 |
| Resists | First : | 23.31 | Second : | 26.56 |
| Pivot price | 21.44  |
|||
| Supports | First : | 18.04 | Second : | 15.01 |
| MAs | MA(5) : | 20.18 |
MA(20) : | 21.79 |
| MA(100) : | 25.26 |
MA(250) : | 19.52 |
|
| MACD | MACD : | -1.1 |
Signal : | -1.1 |
| %K %D | K(14,3) : | 37.6 |
D(3) : | 24.1 |
| RSI | RSI(14): 46 |
|||
| 52-week | High : | 33 | Low : | 7.92 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PHVS ] has closed above bottom band by 47.0%. Bollinger Bands are 13.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 24.23 - 24.32 | 24.32 - 24.42 |
| Low: | 20.33 - 20.42 | 20.42 - 20.52 |
| Close: | 21.13 - 21.28 | 21.28 - 21.43 |
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
Tue, 23 Apr 2024
Pharvaris (NASDAQ:PHVS) Stock Rating Reaffirmed by Morgan Stanley - Defense World
Thu, 11 Apr 2024
Pharvaris Excels in HAE Treatment Advances - TipRanks.com - TipRanks
Sat, 16 Mar 2024
Private equity firms who have a significant stake must be disappointed along with institutions after Pharvaris N.V.'s ... - Simply Wall St
Tue, 23 Jan 2024
Pharvaris (PHVS) Up as FDA Lifts Clinical Hold on HAE Program - Yahoo Finance
Thu, 07 Dec 2023
Biotech Stock Roundup: EXEL Partners RCUS for Study, PHVS & EYPT Gain on Study Data - Yahoo Finance
Wed, 06 Dec 2023
Crude Oil Down 4%; Pharvaris Shares Spike Higher - Markets Insider
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 54 (M) |
| Shares Float | 22 (M) |
| Held by Insiders | 6 (%) |
| Held by Institutions | 83.2 (%) |
| Shares Short | 10 (K) |
| Shares Short P.Month | 102 (K) |
| EPS | -2.81 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.34 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -21.4 % |
| Return on Equity (ttm) | -37.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -93 (M) |
| Levered Free Cash Flow | -55 (M) |
| PE Ratio | -7.58 |
| PEG Ratio | -0.4 |
| Price to Book value | 2.9 |
| Price to Sales | 0 |
| Price to Cash Flow | -12.32 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|